The Department of Oncology (the Department of Immunotherapy) of the Second Hospital of Hebei Medical University is a comprehensive treatment department for tumors with immunotherapy as the main treatment.

We have advanced clinical medical technology and reasonable structure of professional talents. At present, we have 20 beds and a 180 square meters of Ultra Clean Laboratory for Cellular Immunotherapy Research in line with GMP standards. We own more than 20 sets of large-scale medical scientific research equipment including multi-function blood cell separator, flow cytometer, cryogenic refrigerator, liquid nitrogen storage equipment, high-speed cryogenic centrifuge. There are 6 doctors in our department, including 1 chief physician, 3 attending physicians and 2 resident doctors. Among our staff, 1 possesses doctoral degree, 5 possess master's degree. We also own 1 master's tutor, 17 nursing and technical personnel, and currently1 person is reading for master's degree.

Since 2003, the Surgical Research Center of the Second Hospital of Hebei Medical University has undergone six years of research and research, and has digested and absorbed the research progress of basic immunology, oncology and molecular biology in the past ten years, and deeply understood the interaction between the immune system and tumor cells. On the basis of above, a large number of basic and preclinical studies on tumor immunotherapy have been carried out, and more than 20 papers have been published. The results show that a series of tumor microenvironment interference techniques such as Treg and MDSC, inducing calreticulin CRT membrane translocation and enhancing tumor cell immunogenicity can improve the immunity of the body's own immune system to tumors, rebuild and restore the immune system's ability to recognize, kill and inhibit tumor cells to make the tumor patient control tumor cells. Based on this theory of tumor immunotherapy, an independent and innovative "TMDIC: Cellular Immunological Intervention-mediated Cellular Immunotherapy Technology" was established. After strict discussion by the expert group of our hospital and approval of  our hospital committee, the Department of Oncology (the Department of Immunotherapy) of the Second Hospital of Hebei Medical University was officially established in 2009, which realized the transformation of research results into clinical practice. At the same time, we also created a clinical specialty in tumor comprehensive treatment with immunotherapy as our technical specialty. With this technology, a variety of tissue-derived solid tumors and malignant lymphomas can be treated, and some patients with advanced tumors can achieve long-term tumor-bearing survival. If postoperative tumor patients combined with immunotherapy, the recurrence rate can be decreased greatly within 2 years, and the 5-year survival rate can be increased.

The current precision tumor therapy TMDIC technology is based on NGS, PDX and HFSRT, and it is dedicated to reconstructing autoimmune anti-tumor ability, helping more patients to ward tumors and achieve tumor-bearing survival.